These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 22781742)

  • 21. Selective dopamine D3 receptor antagonist YQA14 inhibits morphine-induced behavioral sensitization in wild type, but not in dopamine D3 receptor knockout mice.
    Lv Y; Hu RR; Jing M; Zhao TY; Wu N; Song R; Li J; Hu G
    Acta Pharmacol Sin; 2019 May; 40(5):583-588. PubMed ID: 30224637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents.
    Newman AH; Grundt P; Nader MA
    J Med Chem; 2005 Jun; 48(11):3663-79. PubMed ID: 15916415
    [No Abstract]   [Full Text] [Related]  

  • 23. Dopamine D3 receptor binding of (18)F-fallypride: Evaluation using in vitro and in vivo PET imaging studies.
    Mukherjee J; Constantinescu CC; Hoang AT; Jerjian T; Majji D; Pan ML
    Synapse; 2015 Dec; 69(12):577-91. PubMed ID: 26422464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GPCR targeted library design: novel dopamine D3 receptor ligands.
    Böcker A; Sasse BC; Nietert M; Stark H; Schneider G
    ChemMedChem; 2007 Jul; 2(7):1000-5. PubMed ID: 17477344
    [No Abstract]   [Full Text] [Related]  

  • 25. Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders.
    Heidbreder CA; Newman AH
    Ann N Y Acad Sci; 2010 Feb; 1187():4-34. PubMed ID: 20201845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopamine D3 receptor partial agonist LS-3-134 attenuates cocaine-motivated behaviors.
    Powell GL; Bonadonna JP; Vannan A; Xu K; Mach RH; Luedtke RR; Neisewander JL
    Pharmacol Biochem Behav; 2018 Dec; 175():123-129. PubMed ID: 30308214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel Dual-Target μ-Opioid Receptor and Dopamine D
    Bonifazi A; Battiti FO; Sanchez J; Zaidi SA; Bow E; Makarova M; Cao J; Shaik AB; Sulima A; Rice KC; Katritch V; Canals M; Lane JR; Newman AH
    J Med Chem; 2021 Jun; 64(11):7778-7808. PubMed ID: 34011153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The D2/D3 agonist PD128907 (R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol) inhibits stimulated pyloric relaxation and spontaneous gastric emptying.
    Kashyap P; Micci MA; Pasricha S; Pasricha PJ
    Dig Dis Sci; 2009 Jan; 54(1):57-62. PubMed ID: 18600456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909.
    Rothman RB; Glowa JR
    Mol Neurobiol; 1995; 11(1-3):1-19. PubMed ID: 8561954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis and preliminary bioactivity evaluation of bitopic benzopyranomorpholine analogues as selective dopamine D3 receptor ligands as anti-drug addiction therapeutic agents.
    Cai J; Huang M; Wang Y; Chen X; Ji M
    Bioorg Med Chem Lett; 2021 Sep; 48():128269. PubMed ID: 34284107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selectivity and activation of dopamine D3R from molecular dynamics.
    Feng Z; Hou T; Li Y
    J Mol Model; 2012 Dec; 18(12):5051-63. PubMed ID: 22752545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice.
    Song R; Yang RF; Wu N; Su RB; Li J; Peng XQ; Li X; Gaál J; Xi ZX; Gardner EL
    Addict Biol; 2012 Mar; 17(2):259-73. PubMed ID: 21507153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D
    Kumar V; Moritz AE; Keck TM; Bonifazi A; Ellenberger MP; Sibley CD; Free RB; Shi L; Lane JR; Sibley DR; Newman AH
    J Med Chem; 2017 Feb; 60(4):1478-1494. PubMed ID: 28186762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dopamine D3 receptor agents as potential new medications for drug addiction.
    Le Foll B; Schwartz JC; Sokoloff P
    Eur Psychiatry; 2000 Mar; 15(2):140-6. PubMed ID: 10881212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopamine D3 as well as D2 receptor ligands attenuate the cue-induced cocaine-seeking in a relapse model in rats.
    Gál K; Gyertyán I
    Drug Alcohol Depend; 2006 Jan; 81(1):63-70. PubMed ID: 16005579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Highly Selective Dopamine D
    Reilly SW; Griffin S; Taylor M; Sahlholm K; Weng CC; Xu K; Jacome DA; Luedtke RR; Mach RH
    J Med Chem; 2017 Dec; 60(23):9905-9910. PubMed ID: 29125762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Long-Acting D3 Partial Agonist MC-25-41 Attenuates Motivation for Cocaine in Sprague-Dawley Rats.
    Powell GL; Namba MD; Vannan A; Bonadonna JP; Carlson A; Mendoza R; Chen PJ; Luetdke RR; Blass BE; Neisewander JL
    Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32708461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopamine D4 receptors in psychostimulant addiction.
    Di Ciano P; Grandy DK; Le Foll B
    Adv Pharmacol; 2014; 69():301-21. PubMed ID: 24484981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advances and challenges in the search for D
    Moritz AE; Free RB; Sibley DR
    Cell Signal; 2018 Jan; 41():75-81. PubMed ID: 28716664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.
    Heidbreder CA; Gardner EL; Xi ZX; Thanos PK; Mugnaini M; Hagan JJ; Ashby CR
    Brain Res Brain Res Rev; 2005 Jul; 49(1):77-105. PubMed ID: 15960988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.